Lees-Rolfe Garth bought IKT
January 3, 2025 · Form 4 insider transaction
Lees-Rolfe Garth bought 470,861 shares of Inhibikase Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
470,861
Price
$0.00
Total value
N/A
InsiderLees-Rolfe Garth
RoleOfficer
SecurityStock Option (Right to Buy)
Transaction codeA: Grant or award
Transaction dateJanuary 3, 2025
Filing dateJanuary 7, 2025
Shares owned after470,861
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The options vested and became exercisable on October 9, 2024.